Brigatinib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.Brigatinib Nitroso Impurity 2is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Brigatinib Nitroso Impurity 2 CAS NO:NA chemically represented as N-(5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)-N-(2-(dimethylphosphoryl) phenyl)nitrous amide . Synchemia is the leading manufacturing and exporter of Brigatinib Nitroso Impurity 2 . We supply Brigatinib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141907 |
| CAS No | NA |
| Mol.F. | C20H22N6O5 |
| Mol.Wt. | 426.4g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141908 |
| CAS No | NA |
| Mol.F. | C20H24N6O4 |
| Mol.Wt. | 412.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141909 |
| CAS No | NA |
| Mol.F. | C18H20N6O3 |
| Mol.Wt. | 368.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141910 |
| CAS No | NA |
| Mol.F. | C18H19N7O4 |
| Mol.Wt. | 397.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141911 |
| CAS No | NA |
| Mol.F. | C26H22FN3O2 |
| Mol.Wt. | 427.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141912 |
| CAS No | NA |
| Mol.F. | C33H33FN3O6 |
| Mol.Wt. | 586.6 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141913 |
| CAS No | NA |
| Mol.F. | C15H17N3O2 |
| Mol.Wt. | 271.3 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0141914 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O2 |
| Mol.Wt. | 336.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141915 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141916 |
| CAS No | NA |
| Mol.F. | C16H20ClN3O3 |
| Mol.Wt. | 337.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141917 |
| CAS No | NA |
| Mol.F. | C16H20ClN5O3 |
| Mol.Wt. | 365.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141918 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O3 |
| Mol.Wt. | 380.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141919 |
| CAS No | NA |
| Mol.F. | C16H21ClN4O |
| Mol.Wt. | 320.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141920 |
| CAS No | NA |
| Mol.F. | C14H16ClN3O2 |
| Mol.Wt. | 293.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141921 |
| CAS No | NA |
| Mol.F. | C18H25ClN4O5S |
| Mol.Wt. | 444.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141922 |
| CAS No | NA |
| Mol.F. | C20H27ClN4O3 |
| Mol.Wt. | 406.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |